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Abstract
Background: This study examines, as a part of the European Union funded Adopting Hospital Based Health Technology
Assessment (AdHopHTA) project, the results and barriers of collaboration between Finnish hospitals and the national
health technology assessment (HTA) agency, Finohta. A joint collaborative HTA program has existed since 2006 between
the Finnish hospitals and the national agency.
Methods: A case study method was used. Information about the collaboration between Finnish hospitals and Finohta
was retrieved from interviews and publications, and categorised per theme. Hypotheses and indicators of successful
collaboration were determined beforehand and reflected on the observations from the interviews and literature.
Results: Overall, 48 collaborative HTA reports have been performed during 7 years of collaboration. However, there were
no clear indications that the use of HTA information or the transparency of decision-making regarding new technologies
would have increased in hospitals. The managerial commitment to incorporate HTAs into the decision-making processes
in hospitals was still low. The quality of the collaborative HTA reports was considered good, but their applicability in the
hospital setting limited. There were differing expectations about the timing and relevance of the content. Signs of role
conflict and mistrust were observed.
Conclusions: Despite collaborative efforts to produce HTAs for hospitals, the impact of HTA information on hospital
decision-making appears to remain low. The difficulties identified in this case study, such as lack of managerial
commitment in hospitals, can hopefully be better addressed in the future with the guidance and tools having
been developed in the AdHopHTA project. Collaboration between hospitals and national HTA agencies remains
important for the efficient sharing of skills and resources.
Keywords: Case study, Collaboration, Evaluation, Health technology assessment, Hospitals, Hospital-based health
technology assessment, Technology
Background
WHO defines health technology as the application of
organized knowledge and skills in the form of medicines,
medical devices, vaccines, procedures and systems de-
veloped to solve a health problem and improve quality
of life. Health Technology Assessment (HTA) is research-
based, practice-oriented evaluation of relevant available
knowledge on both the direct and intended, as well as the
indirect and unintended, consequences of health tech-
nologies [1], in the short and long term [2]. The conse-
quences include clinical benefits and economic and
organizational impact, as well as the social, ethical and
legal implications associated with the health technology
being assessed. The aim of HTA is to provide responses to
the specific questions asked by the decision-makers on the
likely value of health technologies. Methodological rigour
and inclusiveness are required when collecting and ana-
lysing context-specific information for an HTA report.
HTA is generally performed in national or regional
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HTA agencies or units. There are currently 54 mem-
bers from 33 countries around the globe in the Inter-
national Network of Agencies for Health Technology
Assessment (INAHTA) [3]. A European network, the
EUnetHTA, supports collaboration between European
HTA organizations.
HTA performed in the hospital context is termed
hospital-based health technology assessment (HB-HTA).
Although it is usually performed in hospitals, it can also
sometimes be outsourced to independent research bodies.
HB-HTA provides responses to hospital managers’ ques-
tions relating to implementation of new technologies in
their hospitals. Hospitals are generally the entry point for
many new technologies. Therefore, it is necessary that
they have the capability to assess their usefulness in a
scientifically valid manner. The new technologies may re-
place or add on to existing technologies, which means that
decision-makers need to know their value in relation to
the current standard practice in their hospital. Further-
more, the information needs to be in place when imple-
mentation decisions are made in the hospital, which
means that the assessment timelines are usually strict.
The Adopting Hospital Based Health Technology Assess-
ment (AdHopHTA) project 2012–2015 was a European
Union (EU) funded project aiming at strengthening the
production and use of HTA in the hospital setting. As HB-
HTA utilises the same methods and resources as national
HTA, collaboration is likely to be beneficial. One of
AdHopHTA’s aims was to examine the existing interactions
between HB- and national HTA functions in its partner
countries, and the barriers and facilitators of fruitful
collaboration. This case study describing the Finnish
context is part of that exercise.
Finland is a small country with 5.4 million inhabitants.
It has a National Health System funded through taxes
levied by the municipalities. Primary care is currently
mostly provided and arranged by the municipalities. For
the organization of specialized healthcare, the country is
divided into 20 hospital districts funded by the munici-
palities. One hospital district can run several hospitals.
The largest of them, the Hospital District of Helsinki
and Uusimaa, has 24 hospitals throughout the province
of Uusimaa in southern Finland. Altogether, there are
approximately 100 hospitals in the country. Some spe-
cialized medical care services (e.g. organ transplanta-
tions, treatment of severe burns, etc.) are organized on
the basis of special responsibility areas of university hospi-
tals of which there are five. The intention of the present
government is, during the next few years, to integrate pri-
mary care, specialized care and social services together
and divide the country into 15 districts responsible for the
organization of those services.
The national Finnish HTA-agency, Finohta, established
in 1995, is currently hosted by the National Institute of
Health and Welfare. In 2013, there were approximately
20 people working for Finohta (not all full time). Since
2006, Finohta has collaborated with the 20 hospital dis-
tricts of Finland in joint HTA production within the
Managed Uptake of Medical Methods (MUMM) pro-
gram (Fig. 1). The hospitals are responsible for topic
identification as well as formulation and implementation
of recommendations. Finohta carries the responsibility
Fig. 1 Process of Managed Uptake of Medical Methods programme – A joint program between Finnish national agency for health technology
assessment (Finohta) and Finnish hospitals
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of coordination, and provides expertise on literature
search and assessment methodology; the actual assess-
ments are performed jointly [4].
There was very little HTA activity in Finnish hospitals
prior to their involvement in the MUMM program in
2006. The first dedicated physician post for HTA-related
work in a hospital was established in 2001 in Helsinki
University Hospital. Two other university hospitals followed
suit towards the end of the decade. A more rapid and
hospital-centred approach using the mini-HTA form [5]
was proposed in 2012, and has now been adopted by most
of the five university hospital regions. Technologies re-
quiring more thorough evaluation are still intended to
go to the MUMM program.
This case study examines the content of the collaborative
MUMM program after its 7 years of function. Further-
more, it reports how clinicians and healthcare decision-
makers perceive the program and tries to identify the
barriers and facilitators of success.
Methods
This case study employed a multimethod approach and
combined information from a reference search in Medline
and a Finnish health portal (Terveysportti), 12 own inter-
views, and data from 38 interviews performed earlier by
Dr Outi Simonen as part of her doctoral thesis on how
the concept of effectiveness is understood by Finnish
healthcare decision-makers [6]. Information concerning
the MUMM program obtained from all the sources were
grouped into the following themes: history of the collabor-
ation, volume or intensity, content, coordination, impact
on decision-making, perceived or observed benefits, and
drivers and barriers of collaboration. Potential indicators
of successful collaboration as well as other contextual fac-
tors possibly affecting collaboration between hospitals and
HTA agencies were identified prospectively in discussions
within an international team of researchers within the
AdHopHTA project. Based on the information obtained
from the above mentioned sources, hypotheses were
developed about what the determinants of successful
collaboration would be.
Information sources
A PubMed search and 12 interviews were performed in
May–June 2013. The informants were: four clinicians from
Helsinki University Hospital who had been previously in-
volved in MUMM; four current or former employees of
Finohta who had been active in MUMM; three external
stakeholders who had worked for, or otherwise had close
connections with, Finohta; and one lead person from the
HTA unit of the Finnish Medicines Agency (Fimea). Spe-
cific questions were used to stimulate the non-structured
interviews. These were: What are the current interactions
between hospitals and the national HTA agency? Is the
collaboration beneficial? What are the barriers of good col-
laboration? How should the collaboration work? Interviews
were recorded and their content grouped by themes in a re-
port. The report was sent to the interviewee for validation:
only minor corrections or amendments were requested.
One of the informants provided us also with unpublished
information from an internal review of the MUMM pro-
gram based on register data and interviews performed in
2012. This information has later been published as an art-
icle in the Finnish Medical Journal [7]. Moreover, as men-
tioned above, data from 38 previously performed interviews
by Outi Simonen in 2008 as part of her doctoral thesis were
also utilised as they contained questions about knowledge
of the MUMM program [6]. The interviewees of that study
were 13 hospital managers, 12 chief physicians, and 13
nursing directors representing all five university hospital
districts in Finland. Websites of Finnish hospitals and
healthcare research institutions were screened for further
relevant information.
A priori considerations about success of collaboration
Contextual factors potentially affecting the success of
collaboration between hospitals and national HTA units
were identified by the authors in the general HTA litera-
ture on interactions observed in various types of collabo-
rations [8–10]. Identified aspects included the power
and role of HTA information in decision-making at the
national level (including reimbursement and pricing)
and at the hospital level (including clinical implementa-
tion and purchase); size of country; history and volume
of HTA activities nationally and in hospitals; funding
system of HTA activities (closed budgets vs. activity based);
level of centralisation of decision-making in hospitals; and
the spectrum of HTA topics and qualities of assessment
methods and products. These were discussed in an inter-
national team of researchers within the AdHopHTA pro-
ject and, based on these considerations, potential success
indicators for collaboration were proposed and some hy-
potheses suggested. The applied indicators of successful
collaboration are listed in Box 1. The hypothesised predic-
tors of successful collaboration were an established HTA
Box 1 Indicators of successful collaboration in health
technology assessment (HTA) between hospitals and
national HTA units, a priori defined for this study
Collaboration increases the use of HTA in clinical implementation and
purchase decisions in hospitals
Collaboration enhances transparency of decision-making regarding the
implementation and purchase of technologies in hospitals
Collaboration enhances patient safety
Collaboration increases patients’ and the public’s acceptance of
technologies and access to them
Collaboration enhances equity in the society (equal access to treatments)
Collaboration promotes innovation and clinical research
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function, powerful HTA (which has legal mandate), fixed
budgets for HTA function in hospitals, and sharing of indi-
viduals or competence (not only information and data).
Furthermore, a hypothesis was made of a barrier for good
collaboration, and this was the differing expectations of
HTA by the hospital managers and clinicians on the one
hand, and HTA professionals on the other [11].
Results
A PubMed search using the full name and acronym of
MUMM gave no references and a search combining the
search terms ‘HTA’, ‘hospital’ and ‘Finland’ yielded only
one study [12]. The Finnish portal for healthcare profes-
sionals (Terveysportti), which contains information from
the Finnish professional journals that are not Medline
indexed, was consulted using the corresponding Finnish
search terms, and resulted in 13 articles mentioning the
MUMM program [12-24].
History of collaboration
In the early years, the late 1990s and early 2000s, the na-
tional HTA agency, Finohta, provided methodological,
and sometimes also financial support for research pro-
jects in hospitals, mainly for randomised trials and sys-
tematic reviews. The aim was to increase the critical
mass of people able to conduct evaluation research in
Finnish hospitals. According to some of the interviewees,
this activity was considered useful by hospitals and
Finohta but it was stopped due reorganisations and cost
cuttings in the late 2000s.
Since the turn of the millennium, several articles were
published in national professional journals about the im-
portance of systematic evaluation of both new and obso-
lete healthcare technologies, particularly in hospitals. A
structured approach to nationally coordinate the evalu-
ation and uptake of new medical technologies was, ac-
cording to the interviewees, clearly desired, especially by
hospital decision-makers. Starting in 2004, a series of
discussions began between hospitals on how to identify
joint topics for assessment. The idea was to encourage
the hospitals to systematically demand critically ap-
praised information on effectiveness, safety and costs of
new technologies, and make joint decisions concerning
their uptake. This was considered necessary for reducing
the geographical variation in the availability of new tech-
nologies and for securing rational use of resources.
Models from other countries, such as Denmark and the
United Kingdom, stimulated the development.
In September 2005, a group of hospital directors de-
cided in their yearly meeting to establish collaboration be-
tween hospital districts and Finohta. The focus of the
programme was set on new technologies. The kick-off
meeting of the new collaboration was in December 2005.
One of the initiators toured the 20 hospital districts of
Finland in 2006 and 2007, promoting the new MUMM
program and engaging the clinicians and hospital man-
agers to its principles. It was clearly outlined from the be-
ginning that MUMM is a joint venture of Finohta and the
hospital districts. Almost all hospital districts agreed to join,
or at least to follow-up on the progress of the program.
MUMM has been a priority function in Finohta and,
despite resource restrictions, the input to MUMM-HTAs
has remained relatively stable during the years. However,
there is currently some pressure for Finohta to prioritise
actions, and therefore some deliberations have been made
to streamline the organisational structure of MUMM and
even diminish MUMM-HTA production.
Content of collaboration
The collaborative MUMM-HTA product is typically a 5-
to 10-page document based on a systematic review of
evidence on effectiveness and safety, and in some cases
the purchasing and running costs of the new technology.
The duration of the overall project, from topic selection
to recommendation, is typically more than 1 year. The
manuscripts of the MUMM-HTAs are submitted for peer
review and published in the Finnish Medical Journal.
Hospitals select the topics, which include mainly med-
ical devices and procedures. Pharmaceuticals were delib-
erately excluded because of resource constraints and
because it was long anticipated that there would be an-
other HTA function within Fimea to cover these later.
This activity is currently being developed by Fimea.
A typical MUMM-HTA is drawn up by two clinical
experts, usually physicians, from hospitals, and two HTA-
specialists and an information specialist from Finohta.
Finohta carries the responsibility of coordination of the
MUMM-HTA projects. Hospital clinicians participate
either as authors or expert consultants in the MUMM-
HTAs. They are recruited specifically for each project,
and their identification is based on individual networks
and contacts of the Advisory Board and Finohta instead
of a formal procedure for nomination.
After the MUMM-HTA has been completed, the hos-
pital districts are responsible for formulation of the rec-
ommendations based on the review. The Advisory Board
of MUMM, which consists of clinical experts from hos-
pitals, prepares a preliminary recommendation which is
then discussed and finalised by the MUMM Board, con-
sisting of chief medical officers of the hospital districts.
Assessment and appraisal are clearly separated in the
MUMM process. This means that the recommendations
are drawn up by other people than those who performed
the review; this has been considered a valid principle. It
was even suggested that the recommendation phase
should be taken out of the current MUMM framework
and performed completely within the hospitals, incorpor-
ating it into the existing meeting and decision-making
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structures. This would probably promote the actual imple-
mentation of the recommendations in hospitals as it
currently discretionary for each hospital to adopt the
MUMM recommendations.
Volume of collaboration
Presently, there are 51 MUMM reviews, based on which
56 recommendations have been given. Some of the re-
views have led to two or three different recommendations
for different indications. Resource input for MUMM has
been greater from the side of Finohta than from the hospi-
tals. During the first 7 years of collaboration, Finohta has
contributed to the collaborative MUMM project a total of
4 to 5 person years and approximately €60,000 annually as
additional direct costs. The hospital districts have overall
provided 90 clinical expert inputs from 30 disciplines
during the same time. The role of the clinical experts from
hospitals is clearly part time, sometimes consultative,
which means that most of the actual work in the assess-
ment phase has been performed in Finohta.
Impact on decision-making
In 2012, an internal evaluation of the MUMM program
was performed using information from hospital registers
and interviews of chief physicians. The aim was to evalu-
ate the perceptions concerning MUMM and its impact
on decision-making in hospitals. Results showed that
57% of chief physicians felt that the content of the
MUMM recommendations are unambiguous, 28% felt
that the recommendations are sufficiently communicated,
and 29% stated that the recommendations are followed
[24]. Hospital managers had a more positive attitude to-
wards HTA activity than other professional groups in
hospitals.
Hospitals are dependent on Finohta’s input in the
MUMM-HTAs and would have difficulties in replacing
the skills and resources provided by Finohta. On the
other hand, the knowledge concerning MUMM in hos-
pitals is still inadequate and the current MUMM-HTAs
and recommendations are scarcely used in decision-
making, which indicates that hospitals do not depend on
the outputs of the collaboration. MUMM is a strategic-
ally important function for Finohta but not essential for
its overall functions. There are other competing national
HTA functions and tasks where the resources could be
shifted if there was no MUMM.
According to most interviewees, the MUMM program
seems to remain poorly known and underutilized in
decision-making in hospitals. One obvious reason is that
the results of MUMM reviews are not systematically re-
quired or used in the clinics’ purchase decisions.
The hospital clinicians pointed out the need for two-
stepped decisions: conditional with the requirement for
re-assessment when new evidence emerges, and final.
MUMM recommendations were considered “too vague”
to sufficiently guide decisions of conditional decisions.
The requirements for data to be collected in the clinic
should be detailed and the timeline agreed upon after
which a reassessment is made before the final decision.
Some clinics have their own systems to collect evidence
and monitor the uptake of new technologies. Teaching
clinics may perform evaluation research, e.g. randomised
controlled trials and systematic reviews, on which to
base their decisions. MUMM seems to be only one of
the possible routes through which evidence is taken into
decision-making in hospitals.
Barriers of collaboration
HTA can still today be considered a threat to clinical
autonomy according to the interviewed clinicians. Ac-
cording to some interviewees, clinics want to be “front-
line” and compete with other clinics about reputation
and staff. The original indications of a new technology
may be narrow and it is tempting to use the technology
also in less severe cases, although expanding indications
at a certain point may cause more harm than good to
the patients. Unnecessary interventions may also be per-
formed for fear of claims, or because of extra earnings
gained. All these issues, together with the constant budget
competition between clinics, maintain the current situ-
ation where physicians are not willing to limit the uptake
or use of new technologies. Furthermore, HTA, and con-
sequently also MUMM, is considered mainly as a tool to
restrict the uptake.
In order to increase the impact of MUMM in decision-
making, hospital clinicians suggested that MUMM reviews
and recommendations should be more regularly commu-
nicated to the clinic management level where the actual
decisions are made. Currently, the information is dis-
tributed to the higher level in the hospital hierarchy,
which is apparently not sufficient [25].
Signs of a role conflict and resulting mistrust occur-
ring between hospitals and Finohta were also identified.
Mistrust is reflected in expressions such as “hospital
clinicians do not feel that they belong to MUMM” and
“Finohta isolates and wants to steer too much the collab-
oration”. On the other side, Finohta staff felt that “hospi-
tals’ attitude is arrogant” and stressed that “Finohta is
not willing to act only in a coordinating role, but have a
say in the design and content of the program in the
future too.”
The slow assessment process is one of the main bar-
riers of MUMM. As the technologies appear and evolve
rapidly, the MUMM reviews should be quicker and
more effort should be made in updating them regularly.
An ideal time span for a MUMM review was originally
set to 6–9 months. In the early years of the program this
was considered a realistic target, but in recent years it
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has become apparent that this is not the case. A slow
and thorough process may be justified, however, if the
topic requires careful and multifaceted evaluation in-
cluding ethical considerations. Nevertheless, for most
topics, a quicker process was required; this is particu-
larly claimed by hospitals but acknowledged by Finohta
as well.
Several factors have led to the process being so slow.
Clinicians participate through minor input, often on their
own time. The staff of Finohta is occupied with several
parallel tasks, and prioritisation has not always favoured
MUMM. With the current resources, the already slow
process of MUMM reviews is not going to be accelerated;
on the contrary, it will most likely be even slower.
Reflecting on the hypotheses
Collaboration between Finnish hospitals and the national
HTA unit cannot be considered successful when looking
at the indicators of success defined for this case study.
The use of HTA information in hospital decision-making
has not increased substantially. The transparency of the
clinical implementation and purchase processes in
hospitals is still poor, which also prevents exact evalu-
ation of the impact of HTA. All other success indica-
tors related to increased patient safety, equity and
acceptability as well as innovation support, could not
be observed in the interviews or published documents
used for this case study.
One of our hypotheses was that powerful HTA, which
has a legal mandate, predicts successful collaboration. In
Finland, HTA has no power as there is no clear legal
obligation to use evidence in decision-making nationally
or in hospitals. This is probably one of the reasons why
the collaboration between hospitals and the national
HTA unit has not been particularly successful. Another
hypothesis, which is supported by the case study in
Finland, is that the differing expectations seemed to be a
major barrier for collaboration.
Finally, it was hypothesised that collaboration be-
tween hospitals and HTA units would be deeper in
countries with a long history of HTA. Finohta is one
of the oldest HTA units in Europe, founded in 1995,
but still the collaboration was not strikingly success-
ful. It was anticipated that sharing people and know-
ledge strengthens the collaboration, but also this
remained unverified by the results of this study. As
mentioned above, Finland is a small country with 5.4
million inhabitants, the funding of HTA is based on
state budget, and the decision-making structures re-
garding technologies for hospitals are extremely de-
centralised. Whether these features represent barriers
of a successful collaboration needs to be confirmed by
further studies.
Discussion
According to our results, the MUMM program does not
appear to have reached its full potential and is still
poorly utilized in decision-making in hospitals. One ex-
planation for that may be the fact that many hospitals
are only starting to require evidence-based appraisal of
scientific literature for their purchase decisions. Another
one is certainly the slow assessment process. When con-
sidering new technologies, the clinicians would, in most
cases, like to have the evidence instantly, they are not
willing to wait for a year.
The gap between research and practice or policy has
also been addressed in earlier studies. A recent systematic
review identified [26], as the most frequently reported
barriers to evidence uptake, poor access to good quality
relevant research and lack of timely research output. Facil-
itators identified were similar to those identified in our
study, namely collaboration between researchers and
policymakers, and improved relationships and skills. In
Denmark, an information campaign to introduce mini-
HTA as a decision support tool for the municipalities
was reported to be insufficient, and should have, ac-
cording to the authors, been supplemented with a strat-
egy to secure local political/managerial support and
willingness [27]. Implementation of HTA appears thus
not just to be a question of how to increase the use of evi-
dence in decision-making, but as a matter of reforming
local decision processes [27].
What could be done to overcome the barriers? One
way forward could perhaps be to attempt to address the
needs of decision-makers more directly, e.g. by adding
information on budget impact and organisational issues.
The results of the AdHopHTA project also highlight
other information needs of hospital managers, namely
those related to the strategic and political importance of
the decisions [28]. Comparative national or international
information regarding treatment indications, clinical
outcomes and costs would be essential particularly when
expensive technologies are considered, and would allow
planning of resource allocation on a national level. Rapid
assessment of most new technologies might be more
helpful for decision-makers than a thorough evaluation
of only some. Rapid assessments downloaded into an
easy-to-use common database could be an improvement
despite of the critique concerning their thoroughness.
Hospitals should learn to utilize the work of others and
study the geographical differences in treatment indica-
tions, clinical outcomes and costs in order to identify
the factors that predict most successful function. For
that purpose a centralised function producing information
on treatment outcomes and indications is warranted.
Currently, the National Institute for Health and Welfare
generates some of the information needed, but an even
volume would be desirable.
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Terminology is important. The concepts of HTA,
MUMM and mini-HTA are taken to the hospitals from
the world of HTA. They do not relate to anything famil-
iar for clinicians and may therefore cause natural resist-
ance. In some countries, attempts have been made to
rename HTA-functions; this could also be worth trying
in Finland.
From a hospital point of view, there is no need to
keep the assessment of pharmaceuticals and non-
pharmaceuticals as separate lines of activities, one
involving Finohta and the other Fimea. Although pharma-
ceuticals need to demonstrate efficacy and safety before
market access, the process of their uptake in hospitals is
not clearly different from that of devices and procedures
where less evidence requirements exist [13].
Collaboration in clinical trials could be an area of co-
operation which could be restarted. The MUMM re-
views are able to identify the areas where evidence is
scarce and this information could systematically feed
into the research agendas in hospitals. Some of difficulties
identified in this case study, such as lack of managerial
commitment in hospitals, can hopefully be better ad-
dressed in the future with the guidance and tools being
developed in the AdHopHTA project. Research funds for
hospitals have decreased substantially. It would, therefore,
be particularly important to target the research to fill in
the gaps identified in evidence of effectiveness and safety
of hospital interventions. Reduced clinical research bud-
gets may also lead to a situation where more and more
technologies are taken directly into use without evidence
of their real life effectiveness.
Conclusions
Collaboration between hospitals and national HTA units
is in principal supported in Finland, but the current pro-
gram, in the current societal situation without any clear
legal obligation to use evidence in decision-making, has
not gained sufficient support after the first 7 years of
existence. The most obvious barriers for collaboration
have been the lack of managerial commitment in hospi-
tals, lacking timeliness of the assessments and a role
conflict between the collaborating parties. Moreover,
HTA is not the only route to take evidence into hospital
decisions: activities and structures for this are already in
place in hospitals, although maybe unsystematic and
heterogeneous. A more systematic and shared system
would, in our opinion, better ensure equal access to
technologies in all areas.
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